journal article·2017-09-13

Poly(3,4-ethylenedioxythiophene)-Based Nanofiber Mats as an Organic Bioelectronic Platform for Programming Multiple Capture/Release Cycles of Circulating Tumor Cells

Chia-Cheng Yu, Bo-Cheng Ho, Ruey-Shin Juang, Yu-Sheng Hsiao, R. Venkata Ram Naidu, Chiung-Wen Kuo, Yun-Wen You, Jing-Jong Shyue, Ji-Tseng Fang, Peilin Chen

Publisher page

Abstract

In this investigation, we employed a novel one-step electrospinning process to fabricate poly(ethylene oxide) (PEO)/poly(3,4-ethylenedioxythiophene):polystyrenesulfonate (PEDOT:PSS) core/shell nanofiber structures with improved water resistance and good electrochemical properties and characterized them using scanning electron microscopy, transmission electron microscopy, and time-of-flight secondary ion mass spectrometry imaging. We then integrated a biotinylated poly-(l-lysine-graft-ethylene glycol) (PLL-g-PEG-biotin) coating with three-dimensional (3D) PEDOT-based nanofiber devices for dynamic control over the capture/release performance of rare circulating tumor cells (CTCs) on-chip. The detailed capture/release behavior of the circulating tumor cells was studied using an organic bioelectronic platform comprising PEO/PEDOT:PSS nanofiber mats with 3 wt % (3-glycidyloxypropyl)trimethoxysilane as an additive. We have demonstrated that these nanofiber mats deposited on five-patterned indium tin oxide finger electrodes are excellent candidates for use as functional bioelectronic interfaces for the isolation, detection, sequential collection, and enrichment of rare CTCs through electrical activation of each single electrode. This combination behaved as an ideal model system displaying a high cell-capture yield for antibody-positive cells while resisting the adhesion of antibody-negative cells. Taking advantage of the electrochemical doping/dedoping characteristics of PEDOT:PSS materials, the captured rare cells could be electrically triggered release through the desorption phenomena of PLL-g-PEG-biotin on device surface. More than 90% of the targeted cancer cells were captured on the 3D PEDOT-based nanofiber microfluidic device; over 87% of captured cancer cells were subsequently released for collection; approximately 80% of spiked cancer cells could be collected in a 96-well plate. Therefore, this 3D PEDOT-based nanofiber approach appears to be an economical route for the large-scale preparation of systems for enhancing the downstream characterization of rare CTCs.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Neuroscience and Neural Engineering · 3D Printing in Biomedical Research · Advanced Sensor and Energy Harvesting Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Materials Engineering, Ming Chi University of Technology, Taishan, New Taipei City 24301, Taiwan

Department of Chemical and Materials Engineering, Chang Gung University, Guishan, Taoyuan 33302, Taiwan

Division of Nephrology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan 33305, Taiwan

Research Center for Applied Sciences, Academia Sinica, Taipei 11529, Taiwan

College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan

Funding

Academia Sinica · Chang Gung Memorial Hospital, Linkou · Ministry of Science and Technology, Taiwan

References (43)

Show source-provided references
1. 10.1002/adfm.20137019110.1002/adfm.201370191 ↗
2. 10.1038/nrd435110.1038/nrd4351 ↗
3. 10.1073/pnas.160423111310.1073/pnas.1604231113 ↗
4. 10.1021/acs.chemrev.6b0014610.1021/acs.chemrev.6b00146 ↗
5. 10.1002/adma.20130449610.1002/adma.201304496 ↗
6. 10.1038/nnano.2012.26510.1038/nnano.2012.265 ↗
7. 10.1016/S1474-4422(08)70291-610.1016/S1474-4422(08)70291-6 ↗
8. 10.1002/adma.20070075810.1002/adma.200700758 ↗
9. 10.1002/adma.20110172410.1002/adma.201101724 ↗
10. 10.1039/C5TB00096C10.1039/C5TB00096C ↗
11. 10.1038/nrclinonc.2013.11010.1038/nrclinonc.2013.110 ↗
12. 10.1373/clinchem.2012.19425810.1373/clinchem.2012.194258 ↗
13. 10.1056/NEJMoa04076610.1056/NEJMoa040766 ↗
14. 10.1016/j.trac.2014.02.01710.1016/j.trac.2014.02.017 ↗
15. 10.1016/j.pharmthera.2013.10.00410.1016/j.pharmthera.2013.10.004 ↗
16. 10.1039/C5AN01762A10.1039/C5AN01762A ↗
17. 10.1073/pnas.101253910710.1073/pnas.1012539107 ↗
18. 10.1002/anie.20100585310.1002/anie.201005853 ↗
19. 10.1021/ar500161710.1021/ar5001617 ↗
20. 10.1002/adma.20120318510.1002/adma.201203185 ↗
21. 10.1021/nn505628210.1021/nn5056282 ↗
22. 10.1002/adma.20070041910.1002/adma.200700419 ↗
23. 10.1021/cm402200310.1021/cm4022003 ↗
24. 10.1038/nmat402110.1038/nmat4021 ↗
25. 10.1002/smll.20090186810.1002/smll.200901868 ↗
26. 10.1002/adma.20110003510.1002/adma.201100035 ↗
27. 10.1039/c1lc20675c10.1039/c1lc20675c ↗
28. 10.1016/j.bbagen.2012.08.02810.1016/j.bbagen.2012.08.028 ↗
29. 10.1039/C3TB21491E10.1039/C3TB21491E ↗
30. 10.1021/acsami.6b0091610.1021/acsami.6b00916 ↗
31. 10.1002/adma.20110215110.1002/adma.201102151 ↗
32. 10.1002/smll.20140042910.1002/smll.201400429 ↗
33. 10.1016/j.polymer.2013.09.04610.1016/j.polymer.2013.09.046 ↗
34. 10.1021/ma300598210.1021/ma3005982 ↗
35. 10.1021/ma202385g10.1021/ma202385g ↗
36. 10.1002/polb.2433110.1002/polb.24331 ↗
37. 10.1021/ma991347t10.1021/ma991347t ↗
38. 10.1039/b813079e10.1039/b813079e ↗
39. 10.1016/j.orgel.2014.07.01510.1016/j.orgel.2014.07.015 ↗
40. 10.1016/j.solener.2016.02.00310.1016/j.solener.2016.02.003 ↗
41. 10.1088/0957-4484/19/41/41560310.1088/0957-4484/19/41/415603 ↗
42. van Krevelen D. W. · 1976
43. 10.1021/ac203340810.1021/ac2033408 ↗